Royalty Pharma plc (RPRX)

Market Cap	20.45B
Revenue (ttm)	2.26B
Net Income (ttm)	1.09B
Shares Out	562.24M
EPS (ttm)	2.45
PE Ratio	14.83
Forward PE	7.91
Dividend	$0.88 (2.42%)
Ex-Dividend Date	May 16, 2025

Volume	1,196,376
Open	36.14
Previous Close	36.19
Day's Range	35.96 - 36.43
52-Week Range	24.05 - 36.43
Beta	0.50
Analysts	Strong Buy
Price Target	47.33 (+30.14%)
Earnings Date	Aug 7, 2025

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX
• Website: https://www.royaltypharma.com

Financial Performance

In 2024, Royalty Pharma's revenue was $2.26 billion, a decrease of -3.86% compared to the previous year's $2.35 billion. Earnings were $858.98 million, a decrease of -24.31%.

Analyst Summary

According to 3 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price target is $47.33, which is an increase of 30.14% from the latest price.

Price Target

$47.33

(30.14% upside)

Analyst Consensus: Strong Buy